SCHEMBL3820683

SCHEMBL3820683

CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)NCC(=O)NCCCNCCCCNCCCN

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A5 Q9Y345 2/20 0.49
RELA Q04206 4/20 0.45
CASP2 P42575 1/20 0.44
NAAA Q02083 1/20 0.42
PAOX Q6QHF9 1/20 0.42
GNAI3 P08754 1/20 0.42
GNAO1 P09471 1/20 0.42
GNAI1 P63096 1/20 0.42
DNM1 Q05193 1/20 0.41
GRIA1 P42261 1/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RRM1 P23921 1/20 0.40
KDM4A O75164 1/20 0.40
HIF1A Q16665 1/20 0.40
TET2 Q6N021 1/20 0.40
DOHH Q9BU89 1/20 0.40
EPHX1 P07099 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28347983 0.99 SLC6A5 (0.50) SLC6A5RELACASP2NAAAPAOX
SCHEMBL30997315 0.99 SLC6A5 (0.50) SLC6A5RELACASP2NAAAPAOX
SCHEMBL27490298 0.86 SLC6A5 (0.46) SLC6A5RELACASP2NAAAPAOX
SCHEMBL27817058 0.86 SLC6A5 (0.46) SLC6A5RELACASP2NAAAPAOX
SCHEMBL27509598 0.86 SLC6A5 (0.56) SLC6A5RELACASP2NAAAPAOX
SCHEMBL27771211 0.86 SLC6A5 (0.56) SLC6A5RELACASP2NAAAPAOX
SCHEMBL28817375 0.85 SLC6A5 (0.47) SLC6A5RELACASP2NAAAPAOX
Spermine SCHEMBL7044349 0.85 PAOX (0.45) SLC6A5RELACASP2PAOXGNAI3
SCHEMBL1037232 0.82 SLC6A5 (0.47) SLC6A5RELACASP2NAAAPAOX
SCHEMBL3394523 0.82 SLC6A5 (0.47) SLC6A5RELACASP2NAAAPAOX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115803333-A Trinucleotide cap analogs, their preparation and use 生命技术公司 2023-03-14 CN claimed
CN-114788876-A mRNA medicinal preparation for treating diabetes, preparation method and application thereof 北京医院 2022-07-26 CN claimed
EP-1242609-A2 NOVEL COLLOID SYNTHETIC VECTORS FOR GENE THERAPY Novartis AG (CH) 2002-09-25 EP claimed
WO-2001049324-A2 NOVEL COLLOID SYNTHETIC VECTORS FOR GENE THERAPY NOVARTIS AG (CH) 2001-07-12 WO claimed
CN-120022384-A Use of lipid nanoparticles in tumor treatment 中国医学科学院基础医学研究所 2025-05-23 CN disclosed
CN-119968210-A RNA for preventing or treating tuberculosis 生物技术公司 2025-05-09 CN disclosed
WO-2025092908-A1 MRNA VACCINE FOR TREATING HPV INFECTION-RELATED DISEASES 仁景(苏州)生物科技有限公司 2025-05-08 WO disclosed
CN-119654139-A RNA Lipid Nanoparticles (LNP) comprising poly  oxazoline polymer and/or poly  oxazine polymer 生物技术公司 2025-03-18 CN disclosed
CN-119654167-A Nucleic acid compositions comprising amphiphilic oligoethylene glycol (OEG) conjugated compounds and methods of using such compounds and compositions 生物技术公司 2025-03-18 CN disclosed
CN-116783293-B Recognition sequences in the dystrophin gene engineering with specificity meganuclease 精密生物科学公司 2025-03-18 CN disclosed
WO-2025016210-A1 NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USES THEREOF 复旦大学 2025-01-23 WO disclosed
CN-119278031-A Nucleic acid compositions comprising multivalent anions, such as inorganic polyphosphates, and methods for preparing, storing, and using the same 生物技术公司 2025-01-07 CN disclosed
US-20020001612-A1 Methods of forming protein-linked lipidic microparticles, and compositions thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2002-01-03 US disclosed
US-6210707-B1 LIPID:NUCLEIC ACID COMPLEXES THAT HAVE INCREASED SHELF LIFE AND HIGH TRANSFECTION ACTIVITY IN VIVO THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2001-04-03 US disclosed
EP-1078079-A1 METHODS OF FORMING PROTEIN-LINKED LIPIDIC MICROPARTICLES, AND COMPOSITIONS THEREOF The Regents of the University of California (US) 2001-02-28 EP disclosed
US-6143530-A PLASMIDS FOR THE EXPRESSION OF HETEROLOGOUS POLYPETIDES; FOR TREATING OR PREVENTING GENETIC DISORDERS, CANCER, COAGULATION DEFECTS, VIRAL INFECTIONS AND USE IN VETERNINARY MEDICINE; ANTICARCINOGENIC AGENTS RHONE-POULENC RORER S.A. (FR) 2000-11-07 US disclosed
US-6071533-A Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-06-06 US disclosed
WO-1999058694-A1 METHODS OF FORMING PROTEIN-LINKED LIPIDIC MICROPARTICLES, AND COMPOSITIONS THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-11-18 WO disclosed
EP-0956001-A1 PREPARATION OF STABLE FORMULATIONS OF LIPID-NUCLEIC ACID COMPLEXES FOR EFFICIENT $i(IN VIVO) DELIVERY The Regents of the University of California (US) 1999-11-17 EP disclosed
WO-1998020857-A1 PREPARATION OF STABLE FORMULATIONS OF LIPID-NUCLEIC ACID COMPLEXES FOR EFFICIENT IN VIVO DELIVERY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-05-22 WO disclosed